Showing results (141-150 of 396) with videos related to

Sort By:
Pageof 40
Oncoimmunology|November 20, 2013
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytesZachary A Cooper, Dennie T Frederick, Vikram R Juneja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Phase II trial of sorafenib in advanced thyroid cancerVandana Gupta-Abramson, Andrea B Troxel, Anoma Nellore, et al.
Clinical Chemistry|December 9, 2023
MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort StudiesTimothy Blewett, Justin Rhoades, Ruolin Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanomaMary M McCarthy, Kyle A DiVito, Mario Sznol, et al.
Plos One|August 13, 2013
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxelLucia B Jilaveanu, Fengmin Zhao, Christopher R Zito, et al.
The Oncologist|May 7, 2017
Impact of Age on Outcomes with Immunotherapy for Patients with MelanomaAllison S Betof, Ryan D Nipp, Anita Giobbie-Hurder, et al.
Circulation Research|June 24, 2006
Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stressCharles Matthews, Isabelle Gorenne, Stephen Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanomaGrant A McArthur, Igor Puzanov, Ravi Amaravadi, et al.
The New England Journal of Medicine|September 8, 2010
Inhibition of mutated, activated BRAF in metastatic melanomaKeith T Flaherty, Igor Puzanov, Kevin B Kim, et al.
British Journal of Cancer|August 17, 2019
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIMKarl D Lewis, James Larkin, Antoni Ribas, et al.
Pageof 40